Refine by
Liver Tissue Articles & Analysis
19 news found
Here below, discover our top three bestselling kits and find the perfect solution for your sample prep! P000912-LYSK1-A.0 Soft tissue homogenizing CK14 The CK14 kit is the perfect solution for soft tissue homogenization, like brain, liver, kidney, skin, plant leaves, mammalian cells and more. Compatible with Precellys Evolution Touch, ...
It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. ...
It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. ...
It is specifically designed to preferentially interact with peripheral CB1 receptors located in the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. ...
“ASC618, a Second-Generation FVIII Gene Therapy for Hemophilia A, Exhibits Major Transduction and Transgene Expression in the Target Liver Tissues: Results of IND-Enabling Pharmacokinetics Studies in Mice and Non-Human Primates” Tweet this A podium presentation entitled “ASC618, a Second-Generation FVIII Gene Therapy for Hemophilia A, ...
Hepatic steatosis can progress to nonalcoholic steatohepatitis (NASH) with fibrosis, and NASH-associated liver failure is one of the leading causes of liver transplant in the United States. ...
Award of NIH Grant to Support Extrahepatic RNA Delivery in Inflammatory Disorders The Company's U.S. subsidiary, Altamira Therapeutics Inc., was recently awarded a Small Business Technology Transfer (STTR) grant by the National Institutes of Health (NIH) to help address the lack of effective systemic delivery technologies for RNA structures that might target diseases occurring beyond the ...
“These molecules represent the first targets under our collaboration with Lilly to address tissues outside the liver, highlighting the further expansion of our growing pipeline of RNAi therapeutics that address multiple tissues and cell types. ...
When measuring fatty liver disease in obese patients, a greater imaging depth (below subcutaneous fat and the liver capsule) results in a more accurate liver health assessment. ...
Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted ...
Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy and liquefy tissue in the liver without incisions, ionizing radiation or heat. ...
With 100 million Americans affected by fatty liver disease, one-fifth will progress to a more severe form of the condition and are at further risk of developing cirrhosis and liver cancer. ...
HistoSonics is pleased to announce that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT) code for histotripsy of the liver. Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy tissue in the liver without ...
The system incorporates major features of living biology, such as pulsatile fluid flow, mechanical and electrical coupling, and physiological tissue-to-fluid and tissue-to-tissue ratios. This supports the development of a large variety of substance assays, ranging from acute and repeated dose toxicity assays to long-term disease treatment ...
“It’s a great honour to be recognized by Rocket Builders for the second year in a row,” said George Aliphtiras, CEO, Sonic Incytes Medical Corp. “Fatty liver disease is an emerging health crisis that affects 1 in 4 people worldwide and, with FDA clearance of VelacurTM, we’re excited to offer health care practitioners a breakthrough, point of care ...
HemoShear scientists created in vitro models of MMA and PA to accurately reflect these human disease states by applying principles of physiological blood flow to human tissue from the livers of MMA and PA patients who underwent transplant. ...
Food and Drug Administration (FDA) to begin a clinical trial of its new platform technology, which is designed to use the science of histotripsy to mechanically destroy targeted liver tissue and tumors, from outside of the body. The study is a multi-center, open label and single arm trial to evaluate the safety and efficacy in destroying liver ...
Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues. ...
ByPoietis
Conshohocken, PA., September 30, 2003-Rex Medical, L.P., today announced the 510K Exempt Status (U.S.) and CE Mark Approval to market the Quadra-Fuse™ Multi-Pronged Injection Needle designed for the infusion of fluids (chemicals, hypertonic saline, etc.) into soft tissue (liver, other organs, etc.). Quadra-Fuse™ technology is an 18 Gauge ...